Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191705 | 0.98 | CCR2 (0.37) | CCR2CCR1CCR5CXCR4CYP1A2 | |
| SCHEMBL21191744 | 0.93 | PRCP (0.40) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL18823467 | 0.93 | PRCP (0.40) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL21743439 | 0.93 | PRCP (0.40) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL22020922 | 0.93 | PRCP (0.40) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL24449512 | 0.93 | PRCP (0.40) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL22024192 | 0.92 | CCR2 (0.39) | CCR2CCR1CCR5CXCR4CYP1A2 | |
| SCHEMBL22023884 | 0.91 | CYP1A2 (0.34) | CCR2CCR1CCR5CXCR4CYP1A2 | |
| SCHEMBL19627720 | 0.91 | PRCP (0.39) | CCR2CCR1CCR5CXCR4PRCP | |
| SCHEMBL19627516 | 0.89 | PRCP (0.35) | CYP1A2PRCPGNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CCR2 521/4885CCR1 543/4885CCR5 59/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CCR2 521/4885CCR1 543/4885CCR5 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.